A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer

This study is comparing a new antibody-drug combination (BL-M07D1) against standard chemotherapy in women with HER2-low breast cancer that has come back or spread. HER2-low means the tumor has a small amount of the HER2 protein — not enough to be considered HER2-positive, but enough to be targeted by this new type of treatment. **You may be eligible if...** - You are a woman aged 18 to 75 - You have been diagnosed with advanced (unresectable, locally recurrent, or metastatic) HER2-low breast cancer - Your cancer has been previously treated with chemotherapy and hormone therapy (if applicable) - You have at least one measurable tumor lesion on imaging - Your overall health is good (ECOG 0–1) - Your organ function (liver, kidneys, blood counts) meets the study requirements **You may NOT be eligible if...** - You are pregnant or breastfeeding - Your cancer is HER2-positive or HER2-zero (no HER2 expression at all) - You have untreated brain metastases - You have received more than the allowed number of prior treatment lines Talk to your doctor to see if this trial is right for you.